Seminars in Oncology
Volume 35, Issue 5 , Pages 470-483 , October 2008

Tomorrow's Cancer Treatments Today: The First 50 Years of the Cancer and Leukemia Group B

  • Mark R. Green

      Affiliations

    • Medical University of South Carolina, Charleston, SC
    • Network for Medical Communication and Research Analytics, Atlanta, GA
    • ,
  • Stephen L. George

      Affiliations

    • Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham, NC
    • ,
  • Richard L. Schilsky

      Affiliations

    • Cancer and Leukemia Group B, Central Office of the Chairman and University of Chicago, Chicago, IL
    • Corresponding Author InformationAddress correspondence to Richard L. Schilsky, MD, Chairman, Cancer and Leukemia Group B, 230 W Monroe St, Suite 2050, Chicago, IL 60601
    • ,
  • Cancer and Leukemia Group B

References 

  1. Schilsky RL, McIntyre OR, Holland JF, et al. A concise history of the Cancer and Leukemia Group B. Clin Cancer Res. 2006;12:3553s–3555s
  2. Frei EF, Holland JF, Schneiderman MA, et al. A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood. 1958;13:1126–1148
  3. Larson RA, Stone RM, Mayer RJ, et al. Fifty years of clinical research by the Leukemia Committee of the Cancer and Leukemia Group. Clin Cancer Res. 2006;12:3556s–3563s
  4. Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood. 1981;58:1203–1212
  5. Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood. 1991;78:2520–2526
  6. Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or Adriamycin for therapy of acute myelocytic leukemia: a CALGB study. [CALGB study 7721] Blood. 1982;60:454–462
  7. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. [CALGB 8525] N Engl J Med. 1994;331:896–903
  8. Gottlieb AJ, Weinberg V, Ellison RR, et al. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by CALGB. [CALGB 7612] Blood. 1984;64:267–274
  9. Bloomfield CD, Mrozek K, Caliguiri MA. Cancer and Leukemia Group B Correlative Science Committee: major accomplishments and future directions. Clin Cancer Res. 2006;12:3564s–3571s
  10. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. [CALGB 8525 and 8461] Cancer Res. 1998;58:4173–4179
  11. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. [CALGB 9191] N Engl J Med. 1997;337:1021–1028
  12. Tallman MS, Anderson JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia: long term outcome and prognosis factor analysis from the North American Intergroup protocol. [CALGB 9191] Blood. 2002;100:4298–4302
  13. Powell BL, Moser B, Stock W, et al. Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup protocol C9710. J Clin Oncol. 2007;25(Suppl 18):2
  14. Rai KR, Peterson BL, Kolitz JE, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. [CALGB 9011] N Engl J Med. 2000;343:1750–1757
  15. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. (9221) J Clin Oncol. 2002;20:2429–2440
  16. Kornblith AB, Herndon JE, Silverman LR, et al. The impact of 5-azacitidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. [CALGB 9221] J Clin Oncol. 2002;20:2441–2452
  17. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478–1484
  18. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003;21:607–614
  19. Hudis CA, Winer EP. Cancer and Leukemia Group B Breast Committee: decades of progress and plans for the future. Clin Cancer Res. 2006;12:3576s–3580s
  20. Small EJ, Halabi S, Kantoff P, et al. Activities and accomplishments of the Cancer and Leukemia Group B Genitourinary Committee. Clin Cancer Res. 2006;12:3596s–3600s
  21. Goldberg RM, Niedzwiecki D, Bertagnolli M, et al. Cancer and Leukemia Group B Gastrointestinal Committee. Clin Cancer Res. 2006;12:3589s–3595s
  22. Vokes EE, Perry MC, Kindler HL, et al. The Cancer and Leukemia Group B Respiratory Committee. Clin Cancer Res. 2006;12:3581s–3588s
  23. Wood W, Budman D, Korzun A, et al. Dose and dose intensity trial of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994;330:1253–1259
  24. Thor A. HER2: a discussion of testing approaches in the USA. Ann Oncol. 2001;12(Suppl 1):S101–S107
  25. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–983
  26. Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007;357:1496–1506
  27. Winer E, Berry D, Duggan D, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342. J Clin Oncol. 2004;22:2061–2068
  28. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol. 2003;21:1431–1439
  29. Peters WP, Rosner GL, Vredenburgh JJ, et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005;23:2191–2200
  30. Linker C, Hurd D. The Cancer and Leukemia Group B Transplant Committee. Clin Cancer Res. 2006;12:3535s–3537s
  31. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113:723–731
  32. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small cell carcinoma of the lung: Cancer and Leukemia Group B study 8083. N Engl J Med. 1987;316:912–918
  33. Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265–271
  34. Choi NC, Herndon JE, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol. 1988;16:3528–3536
  35. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 2006;88:1210–1215
  36. Gaspar LE, Chansky K, Albain KS, et al. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol. 2005;23:2955–2961
  37. Kim K, Tsiatis AA. Study duration for clinical trials with survival response and early stopping rule. Biometrics. 1990;46:81–92
  38. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940–945
  39. Le Chevalier T, Arriagada R, Tarayre M, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst. 1992;84:58
  40. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995;87:198–205
  41. Clamon G, Herndon J, Cooper R, et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol. 1999;17:4–11
  42. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692–2699
  43. Vokes EE, Herndon JE, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007;25:1698–1704
  44. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol. 2004;22(Suppl 14):7019
  45. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol. 2006;24(Suppl 18):7007
  46. Kosty MP, Fleishman SB, Herndon JE, et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol. 1994;12:1113–1120
  47. Lilenbaum RC, Herndon JE, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the Cancer and Leukemia Group B. (study 9730) J Clin Oncol. 2005;23:190–196
  48. Steele GD, Herndon JE, Bleday R, et al. Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann Surg. 1996;6:433–441
  49. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994;331:502–507
  50. Haller DJ, Catalano PG, Mcdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005;23:8671–8678
  51. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan plus fluorouracil/leucovorin alone (FL) in stage III colon cancer. (Intergroup trial CALGB C89803) Proc Am Soc Clin Oncol. 2004;22:245s
  52. Kemeny N, Niedzwiecki D, Hollis D, et al. Hepatic arterial infusion (HAI) versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life (QOL), and molecular markers. J Clin Oncol. 2006;24:1395–1403
  53. Krasna M, Tepper JE, Niedzwiecki D, et al. Trimodality therapy is superior to surgery alone in esophageal cancer: results of CALGB 9781. [abstract 4] Proceedings of the 2006 Gastrointestinal Cancers Symposium. 2006;Jan 26-28; San Francisco, CA
  54. Watanabe T, Wu T-T, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001;344:1196–1206
  55. Arnold CN, Goel A, Compton C, et al. Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. Cancer Biol Ther. 2004;3:73–78
  56. Heinrich MC, Shoemaker JS, Corless CL, et al. Correlation of clinical response to imatinib mesylate (IM) and tumor genotype in patients treated with IM for metastatic GI stromal tumors (GISTs). Proc Am Soc Clin Oncol. 2005;23:7
  57. Small EJ, Halabi S, Ratain M, et al. A phase III study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of CALGB 9480. J Clin Oncol. 2002;20:3369–3375
  58. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res. 2001;7:1932–1936
  59. Small EJ, Halabi S, Dawson NA, et al. A phase III trial of antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: results of CALGB 9583. J Clin Oncol. 2004;22:1025–1033
  60. Taplin ME, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androden independent prostate cancer: CALGB 9663. J Clin Oncol. 2003;21:2673–2678
  61. Savarese D, Halabi S, Hars V, et al. A phase II study of docetaxel, estramustine and low dose hydrocortisone in men with hormone refractory prostate cancer: CALGB 9780. J Clin Oncol. 2001;19:2509–2516
  62. Oh WK, Halabi S, Kelly WK, et al. A phase II study of estramustine, docetaxel and carboplatin with G-CSF support in patients with hormone refractory prostate cancer: Cancer and Leukemia Group B 99813. Cancer. 2003;98:2592–2598
  63. Dawson NA, Halabi S, Biggs DD, Kelly WK, Small EJ. A phase II study of estramustine, docetaxel and exisulind in hormone refractory prostate cancer: initial results of CALGB 90004. Proc Am Soc Clin Oncol. 2005;23:415
  64. Picus J, Halabi S, Rini B, et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: initial results of CALGB 90006. Proc Am Soc Clin Oncol. 2003;22:392
  65. Halabi S, Small EJ, Kantoff PW, et al. A prognostic model for predicting overall survival in men with hormone refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232–1237
  66. Stadler WM, Rosner G, Small EJ, et al. Successful implementation of the randomized discontinuation trial design: an application to the study of putative antiangiogenic agent carbxyaminoimidazole (CAI) in renal cell carcinoma: CALGB 69901. J Clin Oncol. 2005;23:3726–3732
  67. Escudier B, Koralewski P, Pluzanska A, et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol. 2007;25(Suppl 18):3
  68. Kohlman LJ. Cancer and Leukemia Group B Surgery Committee. Clin Cancer Res. 2006;12:3622s–3627s
  69. D'Cunha J, Corfits AL, Herndon JE, et al. Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph-node micrometastatic tumor cell burden in stage I non-small cell lung cancer: preliminary results of Cancer and Leukemia Group B trial 9761. J Thorac Cardiovasc Surg. 2002;123:484–491
  70. D'Cunha J, Herndon JE, Herzan DL, et al. Cancer and Leukemia Group B (Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial). Lung Cancer. 2005;48:241–246
  71. Vollmer RT, Herndon JE, D'Cunha J, et al. Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B. (CALGB) 9761 Clin Cancer Res. 2003;9:5630–5635
  72. Dresler CM, Olak J, Herndon JE, et al. Cooperative Groups Cancer and Leukemia Group B Eastern Cooperative Oncology Group North Central Cooperative Oncology Group Radiation Therapy Oncology Group Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005;127:909–915
  73. Krasna MJ, Reed CE, Nedzwiecki D, et al. CALGB Thoracic Surgeons (CALGB 9380: a prospective trial of the feasibility of thoracoscopy/laparoscopy in staging esophageal cancer). Ann Thorac Surg. 2001;71:1073–1079
  74. Swanson SJ, Herndon J, D'Amico A, et al. Results of CALGB 39802: feasibility of video-assisted thoracic surgery (VATS) lobectomy for early stage lung cancer. [abstract 1158] American Society of Clinical Oncology. 2002;Orlando, FL, May 18-21
  75. Jaklitsch MT, Gu L, Harpole DH, et al. Prospective phase II trial of pre-resection thoracoscopic (VATS) restaging following neoadjuvant therapy for IIIA(N2) non-small cell lung cancer (NSCLC): results of CALGB 39803. [abstract 7065] American Society of Clinical Oncology. 2005;Orlando, FL, May 13-17
  76. Freeman AI, Boyett JM, Glicksman AS, et al. Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up. Med Pediatr Oncol. 1997;28:98–107
  77. Glicksman AS, Pajak TF, Gottlieb A, Nisse N, Stutzman L, Cooper MR. Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study. Cancer Treat Rep. 1982;66:1035–1044
  78. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971–977
  79. Ryan DP, Niedzwiecki D, Hollis DR, et al. A phase I/II study of preoperative oxaliplatin (O), 5-fluorouracil (5-FU), and external beam radiation therapy (XRT) in locally advanced rectal cancer: CALGB 89901. [abstract 3560] Proc Am Soc Clin Oncol. 2004;23:260
  80. Paskett ED, Schrag D, Kornblith A, et al. Cancer and Leukemia Group B Cancer Control and Health Outcomes Committee: origins and accomplishments. Clin Cancer Res. 2006;12:3601s–3605s
  81. Greenberg DB, Kornblith AB, Herndon JE, et al. Quality of life of adult leukemia survivors treated on clinical trials of the Cancer and Leukemia Group B from 1971-1988: predictors of later psychological distress. Cancer. 1997;80:1936–1944
  82. Kornblith AB, Herndon J, Zuckerman E, et al. Comparison of long-term psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Ann Oncol. 1998;9:297–306
  83. Kornblith AB, Anderson J, Cella DF, et al. Comparison of psychosocial adaptation and sexual function of survivors of advanced Hodgkin's disease treated by MOPP, ABVD, or MOPP alternating with ABVD. Cancer. 1992;70:2508–2516
  84. Kornblith AB, Herndon JE, Silverman LR, et al. The impact of 5-azacytidine on the quality of life of patients with myelodysplastic syndrome [MDS] treated in a randomized phase III trial of the Cancer and Leukemia Group B [CALGB]. J Clin Oncol. 2002;20:2441–2452
  85. Goldman DP, Schoenbaum ML, Potosky AL, et al. Measuring the incremental costs of clinical cancer research. J Clin Oncol. 2001;19:105–110
  86. Weeks JC, Nelson H, Gelber S, Sargent D, Schroeder G COST Study Group. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy versus open colectomy for colon cancer. JAMA. 2001;287:321–328
  87. Lamont EB, Herndon JE, Weeks JC, et al. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005;97:1080–1083
  88. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883–890
  89. Ratain MJ, Miller AA, McLeod HL, et al. The Cancer and Leukemia Group B Pharmacology and Experimental Therapeutics Committee: a historical perspective. Clin Cancer Res. 2006;12:3612s–3616s
  90. Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol. 1998;16:1811–1819
  91. Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol. 2000;18:2780–2787
  92. Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol. 2007;25:3055–3060
  93. Miller AA, Murry DJ, Owzar K, et al. Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301. J Clin Oncol. 2007;25(Suppl):3538
  94. Venook AP, Enders Klein C, Fleming G, et al. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol. 2003;14:1783–1790
  95. Compton C. The Cancer and Leukemia Group B Pathology Committee at 50. Clin Cancer Res. 2006;12:3617s–3621s
  96. Dressler LG, Berry DA, Broadwater G, et al. Comparison of HER2 status by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node positive breast cancer patients. J Clin Oncol. 2005;23:4287–4297
  97. Humphrey P, Halabi S, Picus J, et al. Scatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: a plasma study in CALGB 9480. Proc Am Soc Clin Oncol. 2004;23:A859
  98. Baer MR, George SL, Dodge RK, et al. Phase III trial of the multidrug modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: Cancer and Leukemia Group B study 9720. Blood. 2002;100:1224–1232
  99. Kemeny MM, Peterson BL, Kornblith AB, et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol. 2003;21:2268–2275
  100. Lichtman SM, Hollis D, Miller AA, et al. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology (Cancer and Leukemia Group B (CALGB 9762)). J Clin Oncol. 2006;24:1846–1851
  101. Smith EL, Skosey C, Armer J, et al. The Cancer and Leukemia Group Oncology Nursing Committee (1983-2006): a history of passion, commitment, challenge and accomplishment. Clin Cancer Res. 2006;12:3638s–3641s
  102. Price KC, Barrett BK, Roark JM. Cancer and Leukemia Group B Clinical Research Associates Committee. Clin Cancer Res. 2006;12:3642s–3644s

PII: S0093-7754(08)00165-6

doi: 10.1053/j.seminoncol.2008.07.002

Seminars in Oncology
Volume 35, Issue 5 , Pages 470-483 , October 2008

Article Tools